HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
PharmiWeb,
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS ® in Patients with MET Amplified Gastric Cancer — Follows multiple…
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS ® in Patients with MET Amplified Gastric Cancer — Follows multiple…
Patients whose tumors harbor MET amplification were treated with ORPATHYS monotherapy, reporting an ORR of 50% (10/20, 95% CI…
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR…
HONG KONG, SHANGHAI, FLORHAM PARK, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM…
HONG KONG, SHANGHAI, FLORHAM PARK, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM…
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR…
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer HONG KONG, SHANGHAI…
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer GlobeNewswire 2021-07…
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR…
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR…
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS ® in Patients with MET Amplified Gastric Cancer 2021-07-27 20:00…
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR…
HONG KONG, SHANGHAI, FLORHAM PARK, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("") (Nasdaq/AIM:HCM; HKEX:13…
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR…
HONG KONG, SHANGHAI, FLORHAM PARK, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM:HCM; HKEX:13…
HONG KONG, SHANGHAI, FLORHAM PARK, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HC…